Search

Your search keyword '"Neoplasm Metastasi"' showing total 138 results

Search Constraints

Start Over You searched for: Descriptor "Neoplasm Metastasi" Remove constraint Descriptor: "Neoplasm Metastasi" Topic human Remove constraint Topic: human
138 results on '"Neoplasm Metastasi"'

Search Results

1. Upfront FOLFOXIRI plus bevacizumab and reintroduction after progression versus mFOLFOX6 plus bevacizumab followed by FOLFIRI plus bevacizumab in the treatment of patients with metastatic colorectal cancer (TRIBE2): a multicentre, open-label, phase 3, randomised, controlled trial

2. Genetic trajectory and immune microenvironment of lung-specific oligometastatic colorectal cancer

3. Searching for novel multimodal treatments in oligometastatic pancreatic cancer

4. The senescence-associated secretory phenotype (SASP) from mesenchymal stromal cells impairs growth of immortalized prostate cells but has no effect on metastatic prostatic cancer cells

5. Sleeping beauty genetic screen identifies miR-23b::BTBD7 gene interaction as crucial for colorectal cancer metastasis

6. Bone vascular niche E-selectin induces mesenchymal–epithelial transition and Wnt activation in cancer cells to promote bone metastasis

7. Pembrolizumab monotherapy for previously untreated, PD-L1-positive, metastatic triple-negative breast cancer: cohort B of the phase II KEYNOTE-086 study

8. Equivalent Efficacy but Different Safety Profiles of Gemcitabine Plus Nab-Paclitaxel and FOLFIRINOX in Metastatic Pancreatic Cancer

9. Cancer of unknown primary stem-like cells model multi-organ metastasis and unveil liability to MEK inhibition

10. Effect of Bevacizumab in Combination with Standard Oxaliplatin-Based Regimens in Patients with Metastatic Colorectal Cancer: A Randomized Clinical Trial

11. Trastuzumab deruxtecan (DS-8201) in patients with HER2-expressing metastatic colorectal cancer (DESTINY-CRC01): a multicentre, open-label, phase 2 trial

12. Trefoil factor-1 upregulation in estrogen-receptor positive breast cancer correlates with an increased risk of bone metastasis

13. New development on hysteroscopy for endometrial cancer diagnosis: state of the art

14. Cardio-Metabolic Indices and Metabolic Syndrome as Predictors of Clinical Severity of Gastroenteropancreatic Neuroendocrine Tumors

15. Lumican inhibits in vivo melanoma metastasis by altering matrix-effectors and invadopodia markers

16. Exploring the association between metastatic sites and androgen receptor splice variant 7 (AR-V7) in castration-resistant prostate cancer patients: A meta-analysis of prospective clinical trials

17. The prognostic relevance of HER2-positivity gain in metastatic breast cancer in the ChangeHER trial

18. Advances in paclitaxel combinations for treating cervical cancer

19. Evaluation of KRAS, NRAS and BRAF mutational status and microsatellite instability in early colorectal carcinomas invading the submucosa (pT1): Towards an in-house molecular prognostication for pathologists?

20. Does the Unexpected Presence of Non-organ-confined Disease at Final Pathology Undermine Cancer Control in Patients with Clinical T1N0M0 Renal Cell Carcinoma Who Underwent Partial Nephrectomy?

21. Statin Use and Survival in Patients with Metastatic Castration-resistant Prostate Cancer Treated with Abiraterone Acetate

22. Genomic profiles of primary and metastatic esophageal adenocarcinoma identified via digital sorting of pure cell populations: results from a case report

23. Buparlisib plus fulvestrant versus placebo plus fulvestrant in postmenopausal, hormone receptor-positive, HER2-negative, advanced breast cancer (BELLE-2): a randomised, double-blind, placebo-controlled, phase 3 trial

24. Lac-l-TTA, a novel lactose-based amino acid–sugar conjugate for anti-metastatic applications

25. The Clinical Efficacy of Enzalutamide in Metastatic Prostate Cancer: Prospective Single-center Study

26. Extraskeletal osteosarcoma

27. Chemotherapy versus endocrine therapy as first-line treatment in patients with luminal-like HER2-negative metastatic breast cancer: A propensity score analysis

28. Alpha-enolase (ENO1) controls alpha v/beta 3 integrin expression and regulates pancreatic cancer adhesion, invasion, and metastasis

29. Third- and later-line treatment in advanced or metastatic gastric cancer: a systematic review and meta-analysis

30. Locoregional delivery of CAR T cells to the cerebrospinal fluid for treatment of metastatic medulloblastoma and ependymoma

31. Anti-EGFR-resistant clones decay exponentially after progression: Implications for anti-EGFR re-challenge

32. Vinflunine in Metastatic Urothelial Carcinoma of the Bladder in Progression after a Platinum-Containing Regimen

33. Trastuzumab emtansine for residual invasive HER2-positive breast cancer

34. miR‑494.3p expression in synovial sarcoma: Role of CXCR4 as a potential target gene

35. Colonic metastasis from breast carcinoma detection by CESM and PET/CT: A case report

36. MiR-205-5p inhibition by locked nucleic acids impairs metastatic potential of breast cancer cells

37. Yin Yang I as an Epimodulator of miRNAs in the Metastatic Cascade

38. New and emerging treatments for metastatic Merkel cell carcinoma

39. Dabrafenib-trametinib combination in 'field-practice': An Italian experience

40. Possible delayed diagnosis and treatment of metastatic differentiated thyroid cancer by adopting the 2015 ATA guidelines

41. Pulmonary recurrence from prostate cancer and biochemical remission after metastasis directed therapy. A case report

42. Controversies in monitoring metastatic breast cancer during systemic treatment. Results of a GIM (Gruppo Italiano Mammella) survey

43. Treatment of advanced breast cancer with a metronomic schedule of oral vinorelbine: what is the opinion of Italian oncologists?

44. A novel CCK2/gastrin receptor-localizing radiolabeled peptide probe for personalized diagnosis and therapy of patients with progressive or metastatic medullary thyroid carcinoma: A multicenter phase I GRAN-T-MTC study

45. Surgery of the primary tumor in de novo metastatic breast cancer: To do or not to do?

46. Metastasis-directed Therapy of Regional and Distant Recurrences After Curative Treatment of Prostate Cancer: A Systematic Review of the Literature

47. 20-year risks of breast-cancer recurrence after stopping endocrine therapy at 5 years

48. New surgical approaches for clinically high-risk or metastatic prostate cancer

49. Eribulin as an effective monotherapy in a chemo-pretreated woman with metastatic breast cancer: a case report

50. Quality analysis of population-based information on cancer stage at diagnosis across Europe, with presentation of stage-specific cancer survival estimates: A EUROCARE-5 study

Catalog

Books, media, physical & digital resources